NURIX THERAPEUTICS, INC. (NRIX) FY2026 Q3 Balance Sheet

Balance Sheet

As of 2026-08-31

Swipe to see the full flow
NURIX THERAPEUTICS, INC. (NRIX) FY2026 Q3 Balance SheetBalance sheet as of 2026-08-31. The chart shows assets, liabilities and equity at that date.Current liabilities$130.74 MCurrent assets$1.10 BLiabilities$226.99 MAssets$1.20 BNon-current liabilities$96.25 MEquity$968.31 MGross equity(calculated)$1.60 BNon-current assets$91.61 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsMarketable securities, currentPrepaid expenses and other current assetsAccounts receivableOperating lease right-of-use assetsProperty and equipment, netMarketable securities, non‑currentOther assetsRestricted cashAccrued expenses and other current liabilitiesAccounts payableDeferred collaboration funding, currentDeferred revenue, currentOperating lease liabilities, currentOperating lease liabilities, net of current portionDeferred collaboration funding, net of current portionDeferred revenue, net of current portionAdditional paid-in capitalCommon stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive income (loss)Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities$63.67 MCurrent liabilitiesCurrent liabilities$130.74 MAccounts payableAccounts payable$32.98 MDeferred collaboration funding, currentDeferred collaboration funding, current$22.23 MCurrent assetsCurrent assets$1.10 BLiabilitiesLiabilities$226.99 MDeferred revenue, currentDeferred revenue, current$8.61 MOperating lease liabilities, currentOperating lease liabilities, current$3.24 MCash and cash equivalentsCash and cash equivalents$720.24 MAssetsAssets$1.20 BOperating lease liabilities, net of current portionOperating lease liabilities, net of current portion$62.09 MNon-current liabilitiesNon-current liabilities$96.25 MEquityEquity$968.31 MDeferred collaboration funding, net of current portionDeferred collaboration funding, net of current portion$23.38 MDeferred revenue, net of current portionDeferred revenue, net of current portion$10.78 MGross equity (calculated)Gross equity(calculated)$1.60 BMarketable securities, currentMarketable securities, current$328.01 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$35.44 MAccounts receivableAccounts receivable$20.00 MOperating lease right-of-use assetsOperating lease right-of-use assets$48.63 MProperty and equipment, netProperty and equipment, net$19.41 MNon-current assetsNon-current assets$91.61 MAdditional paid-in capitalAdditional paid-in capital$1.60 BMarketable securities, non‑currentMarketable securities, non‑current$14.83 MOther assetsOther assets$7.95 MRestricted cashRestricted cash$782.00 KCommon stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectivelyCommon stock$109.00 KAccumulated deficitAccumulated deficit−$630.13 MAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$210.00 K
Chart details

NURIX THERAPEUTICS, INC. (NRIX) FY2026 Q3 Balance Sheet

Balance sheet as of 2026-08-31. The chart shows assets, liabilities and equity at that date.

Assets
1,195,298,000 US dollars
Current assets
1,103,692,000 US dollars
Non-current assets
91,606,000 US dollars
Liabilities
226,987,000 US dollars
Current liabilities
130,742,000 US dollars
Non-current liabilities
96,245,000 US dollars
Equity
968,311,000 US dollars
Cash and cash equivalents
720,242,000 US dollars
Marketable securities, current
328,013,000 US dollars
Prepaid expenses and other current assets
35,437,000 US dollars
Accounts receivable
20,000,000 US dollars
Operating lease right-of-use assets
48,631,000 US dollars
Property and equipment, net
19,407,000 US dollars
Marketable securities, non‑current
14,832,000 US dollars
Other assets
7,954,000 US dollars
Restricted cash
782,000 US dollars
Accrued expenses and other current liabilities
63,674,000 US dollars
Accounts payable
32,984,000 US dollars
Deferred collaboration funding, current
22,233,000 US dollars
Deferred revenue, current
8,610,000 US dollars
Operating lease liabilities, current
3,241,000 US dollars
Operating lease liabilities, net of current portion
62,091,000 US dollars
Deferred collaboration funding, net of current portion
23,376,000 US dollars
Deferred revenue, net of current portion
10,778,000 US dollars
Additional paid-in capital
1,598,540,000 US dollars
Common stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectively
109,000 US dollars
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of August 31, 2026 and November 30, 2025; no shares issued and outstanding as of August 31, 2026 and November 30, 2025
0 US dollars
Accumulated deficit
negative 630,128,000 US dollars
Accumulated other comprehensive income (loss)
negative 210,000 US dollars
Gross equity (calculated)
1,598,649,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
NURIX THERAPEUTICS, INC. (NRIX) FY2026 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!